The American College of Cardiology (ACC) has published its “2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis” in the Journal of the American College of Cardiology.
A large, multicenter cohort study supports phenotype-based screening of first-degree family members of patients with confirmed DCM without input, necessarily, from genetic testing.
Share this article
Share this article
BETHESDA, Md., May 20, 2021 /PRNewswire/ The American College of Medical Genetics and Genomics (ACMG) has just released an updated policy statement and gene list for the reporting of secondary findings (SF). Together, these two documents update the recommendations for SF reporting and unveil the highly anticipated recommended minimum gene list
(SF v3.0) for reporting secondary findings in clinical exome and genome sequencing. The ACMG also declares its intent to update the SF gene list now annually, with a goal of publishing the updated list each January.
Genetics in Medicine. Our group worked very hard on this update, taking a thoughtful and careful approach that balances the goals of keeping it as a minimum list while also providing results that will impact patients and their families in a positive way, said lead author and co-chair of the ACMG SFWG, David T. Miller, MD, PhD, FACMG.